Show simple item record

AuthorAnsari, Abdul Wahid
AuthorAhmad, Fareed
AuthorAlam, Majid Ali
AuthorRaheed, Thesni
AuthorZaqout, Ahmed
AuthorAl-Maslamani, Muna
AuthorAhmad, Aamir
AuthorBuddenkotte, Joerg
AuthorAl-Khal, Abdullatif
AuthorSteinhoff, Martin
Available date2024-11-19T11:29:50Z
Publication Date2024-09
Publication NameReviews in Medical Virology
Identifierhttp://dx.doi.org/10.1002/rmv.2578
CitationAnsari, A. W., Ahmad, F., Alam, M. A., Raheed, T., Zaqout, A., Al‐Maslamani, M., ... & Steinhoff, M. (2024). Virus‐Induced Host Chemokine CCL2 in COVID‐19 Pathogenesis: Potential Prognostic Marker and Target of Anti‐Inflammatory Strategy. Reviews in Medical Virology, 34(5), e2578.
ISSN1052-9276
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85202209669&origin=inward
URIhttp://hdl.handle.net/10576/61321
AbstractA wide variety of inflammatory mediators, mainly cytokines and chemokines, are induced during SARS CoV-2 infection. Among these proinflammatory mediators, chemokines tend to play a pivotal role in virus-mediated immunopathology. The C-C chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1) is a potent proinflammatory cytokine and strong chemoattractant of monocytes, macrophages and CD4+ T cells bearing C-C chemokine receptor type-2 (CCR2). Besides controlling immune cell trafficking, CCL2 is also involved in multiple pathophysiological processes including systemic hyperinflammation associated cytokine release syndrome (CRS), organ fibrosis and blood coagulation. These pathological features are commonly manifested in severe and fatal cases of COVID-19. Given the crucial role of CCL2 in COVID-19 pathogenesis, the CCL2:CCR2 axis may constitute a potential therapeutic target to control virus-induced hyperinflammation and multi-organ dysfunction. Herein we describe recent advances on elucidating the role of CCL2 in COVID-19 pathogenesis, prognosis, and a potential target of anti-inflammatory interventions.
SponsorThis work is is supported by: - the research grant (MRC-01-21-874) from the Medical Research Centre, Hamad Medical Corporation, Doha, Qatar to AWA. - the Medical Research Centre grant (MRC\u201001\u201021\u2010874), Hamad Medical Corporation, Doha, Qatar to AWA.
Languageen
SubjectARDS
CCL2
COVID-19
cytokine release syndrome
immunopathogenesis
multi-organ dysfunction
TitleVirus-Induced Host Chemokine CCL2 in COVID-19 Pathogenesis: Potential Prognostic Marker and Target of Anti-Inflammatory Strategy
TypeArticle
Issue Number5
Volume Number34
ESSN1099-1654
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record